Upcoming FDA adcomms will test post-Makary independence 

In another sign that FDA is reverting to a more conventional approach to regulation, the agency will hold two advisory committee meetings in July to consider high-profile, controversial approval decisions.

One will center on RP1 vusolimogene oderparepvec from Replimune Group Inc. (NASDAQ:REPL) to treat advanced melanoma. Another will focus on a BLA from Capricor Therapeutics Inc. (NASDAQ:CAPR) for deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). ...